“Will become a CRO specializing in cell·gene therapy”
By Lee, Tak-Sun | translator Alice Kang
22.05.09 06:18:00
가나다라
0
Interview | Director Eun-Kyung Sohn, HCO at Seoul CRO
Part of CHA Medical & Bio Group… has the strength of being able to utilize the internal infrastructure
Will also make efforts to establish a logistics system for cell·gene therapies, which is more difficult than that made for general chemical drugs
▲Director Eun-Kyung Sohn, HCO at Seoul CRO
“I believe the cell·gene therapy market will expand the greatest among biopharmaceuticals. The number of new clinical trials entering the field increased over threefold from 2016, and the role of CROs that have strengths in conducting clinical trials for cell· gene-based therapies will further increase in the coming future.”Director Sohn explained her vision of growing the company into a cell·gene therapy specialized CRO in line with the industry trend. Director Eun-Kyung Sohn, HCO (Head of Clinical Operation·46) at Seoul CRO, joined the company in December last year.
Sohn aims to find a breakthrough in the midst of the intensifying competition in the CRO market by developing Seo
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)